Shares of NATCO Pharma Limited rallied more than 9% after the company received approval from the Central Drugs Standard Control Organization (CDSCO) to manufacture and market generic Semaglutide Injection in India. The company confirmed that the product will be launched in the domestic market in March 2026.
The approval marks NATCO’s entry into one of the fastest-growing segments of diabetes treatment. Semaglutide, a GLP-1 receptor agonist, is prescribed for adults with insufficiently controlled Type 2 diabetes mellitus and is used alongside diet and exercise to improve blood sugar management. With India witnessing a steady rise in diabetes cases, the availability of a generic version is expected to expand patient access to advanced therapies at a potentially more affordable price point.
The development is seen as strategically important for NATCO as GLP-1-based treatments continue to gain traction globally. By adding Semaglutide to its domestic portfolio, the company strengthens its presence in the chronic therapy segment while leveraging its manufacturing and regulatory capabilities.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.